Alere Connect gains FDA approval for MobileLink

[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2013/08/topper-mobilelink1-1140×180.jpg” thumb_width=”175″ /]We had been surprised at how quiet Alere Connect, the former MedApps, has been since its acquisition a year ago. Their latest news is that their newest and quite streamlined gateway hub, Alere MobileLink, has received FDA clearance to add to its recent CE Mark certification, clearing it for introduction in both US and Europe later this year. The US announcement also indicates that it will be packaged with Alere’s INRatio 2 PT/INR Monitor as part of home patient monitoring of anticoagulant medications programs through Alere Home Monitoring. This Editor notes that anticoagulant monitoring is ‘high-value’ and for remote monitoring, fairly different. Like the earlier MedApps HealthPal, it is also ‘vendor neutral’ compatible with multiple telehealth devices for glucose meters, weight scales, blood pressure monitors and pulse oximeters. Much of the emphasis of the new Alere Connect is how it integrates tightly with Alere’s programs and Connected Health informatics, care management and accountable care solutions, which is confirmed by CEO Kent Dicks’ quote included in the release: “The Alere Connected Health platform has the ability to connect flexibly with devices and systems regardless of their manufacturer and origin. The platform captures and analyzes data with robust analytics, and then backs it up with comprehensive health management services.” No information on rollout in UK or Europe. Release.

For long-time followers of MedApps, their HealthPal wireless hub is still being supported by Alere but will not at this point be integrated with INR monitoring. Also pending FDA clearance is a home health information tablet, Alere HomeLink.

Flashback: Integration of devices with service delivery providers was a major point brought up in our discussion of the MedApps acquisition value back in January, What a telehealth device company may be worth.  “What may be a better way is that device developers joint venture themselves from the start with health or service providers. And that those already seeking financing seek provider partners.”–Editor Donna